Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582672 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by Argos Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT01582672 is a Phase 3 study that was terminated before completion, run by Argos Therapeutics. The registered enrollment target is 462 participants.
The verdict
NCT01582672, a Phase 3 study, was terminated before completion, sponsored by Argos Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.
Interventions
- BIOLOGICAL AGS-003
- DRUG Standard Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582672
The ClinicalTrials.gov registry entry for NCT01582672 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGS-003 is the first listed.
NCT01582672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582672 about?
NCT01582672 is a clinical study titled "Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma". This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treat...
What is the current status of trial NCT01582672?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2012-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01582672?
The interventions under investigation include: AGS-003 (BIOLOGICAL), Standard Treatment (DRUG).
Who is sponsoring clinical trial NCT01582672?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.